NEWBRY Stock Overview
Operates as hybrid pharmaceutical company in Sweden, and Scandinavian market.
Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 6/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Newbury Pharmaceuticals AB (publ) Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | SEK 3.86 |
52 Week High | SEK 6.24 |
52 Week Low | SEK 2.40 |
Beta | 1.53 |
11 Month Change | -3.02% |
3 Month Change | 7.22% |
1 Year Change | 23.72% |
33 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -69.37% |
Recent News & Updates
Recent updates
Shareholder Returns
NEWBRY | SE Pharmaceuticals | SE Market | |
---|---|---|---|
7D | -3.5% | -1.2% | -1.9% |
1Y | 23.7% | 37.0% | 21.8% |
Return vs Industry: NEWBRY underperformed the Swedish Pharmaceuticals industry which returned 37% over the past year.
Return vs Market: NEWBRY exceeded the Swedish Market which returned 21.8% over the past year.
Price Volatility
NEWBRY volatility | |
---|---|
NEWBRY Average Weekly Movement | 7.6% |
Pharmaceuticals Industry Average Movement | 11.0% |
Market Average Movement | 5.4% |
10% most volatile stocks in SE Market | 10.9% |
10% least volatile stocks in SE Market | 3.2% |
Stable Share Price: NEWBRY's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: NEWBRY's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2020 | 6 | Lars Minor | www.newburypharma.com |
Newbury Pharmaceuticals AB (publ) operates as hybrid pharmaceutical company in Sweden, and Scandinavian market. It offers oncology, rare diseases, neurology, and other treatment products. The company was incorporated in 2020 and is based in Lund, Sweden.
Newbury Pharmaceuticals AB (publ) Fundamentals Summary
NEWBRY fundamental statistics | |
---|---|
Market cap | SEK 97.03m |
Earnings (TTM) | -SEK 15.40m |
Revenue (TTM) | SEK 36.83m |
2.5x
P/S Ratio-6.1x
P/E RatioIs NEWBRY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
NEWBRY income statement (TTM) | |
---|---|
Revenue | SEK 36.83m |
Cost of Revenue | SEK 20.80m |
Gross Profit | SEK 16.03m |
Other Expenses | SEK 31.44m |
Earnings | -SEK 15.40m |
Last Reported Earnings
Aug 31, 2024
Next Earnings Date
Dec 11, 2024
Earnings per share (EPS) | -0.64 |
Gross Margin | 43.53% |
Net Profit Margin | -41.83% |
Debt/Equity Ratio | 0% |
How did NEWBRY perform over the long term?
See historical performance and comparison